Loading...
Initially published data from the Women's Health Initiative indicated that postmenopausal women who used continuous combined estrogen/progestin (E/P) therapy experienced significantly greater increases in certain adverse outcomes (i.e., coronary events, stroke, venous thrombosis, and breast cancer) than did placebo recipients (Journal Watch Jul 26 2002). Investigators now have examined the data to determine whether any improvement in quality of life had occurred among E/P users.
A total of 16,608 women (age range, 50-79) with intact uteri were assigned to receive 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogesterone acetate or matched placebos daily. Quality-of-life measures (including estimates of general health, vitality, me…